• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
XENT

XENT

Intersect ENT, Inc.

NASDAQHealthcareMedical - DevicesUS

USD28.24

+0.00 (+0.00%)

Company Profile

CEO

Thomas West

IPO Date

2014-07-24

Sector

Healthcare

Industry

Medical - Devices

Exchange

NASDAQ

Country

US

Market Metrics

Open

$28.25

Prev. Close

$28.24

Day Low

$28.23

Day High

$28.25

52W Low

$15.92

52W High

$28.25

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

44.1%

Avg Negative

12.0%

Avg Neutral

44.1%

News Feed

Intersect ENT (XENT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks Investment Research·7/30/2021·↑ positive

U.S Nationwide Commercial Availability of the VenSure™ Balloon Sinus Dilation System and Cube™ Navigation System Highlight Intersect ENT's Continued Commitment to Providing Innovative, Solutions for Patients with Chronic Rhinosinusitis

Business Wire·7/26/2021·↑ positive

Intersect ENT Sees Q2 Sales Lag Wall Street Estimates; Raises $60M In Debt Funding

Benzinga·7/23/2021·↓ negative

Intersect ENT to Report Second Quarter 2021 Financial Results on August 6

Business Wire·7/23/2021·↓ negative

Intersect ENT (XENT) Surges 5.2%: Is This an Indication of Further Gains?

Zacks Investment Research·6/29/2021·↑ positive

Intersect ENT (XENT) Receives CE Mark for PROPEL Contour

Zacks Investment Research·5/24/2021·↑ positive

Intersect ENT Receives CE Mark Approval for PROPEL® Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery

Business Wire·5/20/2021·↑ positive

Intersect ENT (XENT) Q1 Loss Wider Than Expected, Revenues Top

Zacks Investment Research·5/11/2021·↑ positive

Intersect ENT, Inc. (XENT) CEO Tom West on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/10/2021·↓ negative

Intersect ENT (XENT) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research·5/10/2021·↑ positive